Asenapine

Limits on what this shows

• Key negative/null findings: No asenapine-specific study reporting mitochondrial harm, dysfunction, or electron-transport-chain inhibition was located in PubMed (multiple phrasings: "asenapine AND mitochondria", "asenapine AND mitochondrial") or the Crossref API ("asenapine oxidative stress mitochondria", zero asenapine-specific hits among 10 returned records).
• At-risk subgroups: None identified; no human dose-response or subgroup data exists for this finding.
• Counter-evidence on record: None found suggesting mitochondrial harm from asenapine specifically; the only direct evidence located points the other direction.

Regulatory status

Not addressed in the EU or US label; this is investigational in vitro pharmacology, not a labeled effect.

Population evidence

Grossini E, Gramaglia C, Farruggio S, Bellofatto K, Anchisi C, Mary D, Vacca G, Zeppegno P. "Asenapine increases nitric oxide release and protects porcine coronary artery endothelial cells against peroxidation." Vascul Pharmacol. 2014; PMID 24512732. In vitro, non-human (porcine) coronary artery endothelial cell line. The search-accessible abstract snippet reports that asenapine "prevented reactive oxygen species production and glutathione reduction, mitochondrial membrane potential collapse and apoptosis" under a peroxidative/oxidative challenge. Exact concentration range and full peroxidation-model methodology could not be confirmed beyond this snippet in this review (the full PMID detail page returned a bot-verification challenge on every attempt); treat exposure-relevance to typical human plasma levels as unconfirmed.

Mechanism

Named in the source as nitric-oxide-mediated cytoprotection against oxidative/peroxidative endothelial injury, preserving mitochondrial membrane integrity. Not a mitochondrial-toxicity mechanism; no mitochondrial-burden mechanism for asenapine was found in any channel searched.

Counter-evidence held on record

This is not a depletion finding and does not support any supplementation claim. It is a single, non-human, in vitro signal in the protective direction; it should not be read as reassurance of mitochondrial safety either, only as the one data point currently available. See Overlap map: this entry and Oxidative stress rest on the same source.

Limits on what this shows

• Key negative/null findings: PubMed queries for "asenapine" combined with oxidative stress, mitochondria, or antioxidant terms returned only this one drug-specific record; the Crossref API query "asenapine oxidative stress mitochondria" returned zero asenapine-specific records among its top 10 results.
• At-risk subgroups: None identified.
• Counter-evidence on record: None found. No asenapine-specific pro-oxidant finding was located.

Regulatory status

Not addressed in the EU or US label.

Population evidence

Grossini et al., Vascul Pharmacol 2014, PMID 24512732 (see Mitochondrial burden entry for full citation and access caveat). The same report measured reactive oxygen species production and glutathione levels as redox endpoints, both preserved/protected by asenapine in this model.

Mechanism

Nitric-oxide-mediated cytoprotection against peroxidative stress, as named in the source. No oxidative-stress-inducing mechanism for asenapine was found in any channel searched.

Counter-evidence held on record

Not a depletion finding; no antioxidant supplementation claim follows from this. Shares its entire evidentiary basis with Mitochondrial burden above (see Overlap map) and should not be counted as a second, independent confirmation of anything.

Limits on what this shows

• Key negative/null findings: Risperidone, a full D2 antagonist studied in the same Chen et al. cohort, showed no significant copper change, directly arguing against a uniform "antipsychotic lowers copper" class effect and against assuming automatic transfer to every class member, asenapine included.
• At-risk subgroups: None established for asenapine specifically.
• Counter-evidence on record: Confounding by indication is presumed until excluded (Hard Rule 6) for the disease-state finding and has not been excluded; the entire elevated-copper signal may describe schizophrenia or bipolar illness generally rather than any drug's effect, let alone asenapine's. See Overlap map: this entry shares the Saghazadeh et al. 2020 source with Iron below.

Regulatory status

Not addressed in either the EU SmPC or US label; no copper or trace-mineral term appears anywhere in asenapine's adverse-reaction tables at any frequency, directly re-confirmed by fetching both the SAPHRIS and SECUADO DailyMed labels this pass.

Population evidence

Saghazadeh A, Mahmoudi M, Shahrokhi S, et al., "Trace elements in schizophrenia: a systematic review and meta-analysis of 39 studies" (2020, PMID 31800085, N=5151): quoted, "higher levels of copper, lower levels of iron, and lower levels of zinc among patients with schizophrenia vs controls." Disease-state design (schizophrenia versus healthy controls), not an antipsychotic-treatment cohort, so no single drug, including asenapine, was "in the cohort" in the Hard Rule 6 sense; schizophrenia and bipolar I mania/mixed episodes are both within asenapine's own approved indications, so this is the same patient population asenapine treats. Chen X, Li Y, Zhang T, Yao Y, Shen C, Xue Y, Biol Trace Elem Res 2017 (PMID 28470477, DOI 10.1007/s12011-017-1039-6): case-control study, 165 schizophrenia inpatients versus 614 controls, prospective ~3.8-week follow-up through treatment with risperidone, clozapine, or aripiprazole; serum copper significantly decreased after clozapine and aripiprazole specifically (P<0.05), not after risperidone. Asenapine was not in either cohort. Both sources were corroborated by matching PMID/DOI citation in companion antipsychotic dossiers in this same project; this pass's own fresh fetch attempts for both (PubMed, Crossref, OpenAlex) were blocked by HTTP 429 rate limiting despite repeated tries, disclosed here rather than presented as an independent re-verification.

Mechanism

Not established as drug-specific for any single antipsychotic. Copper is an acute-phase reactant that rises with ceruloplasmin under low-grade inflammation, so the disease-state elevation may reflect illness-associated inflammation rather than any drug's pharmacology. For the Chen et al. within-class split, risperidone (a full D2/5-HT2A-dominant antagonist with a comparatively narrow receptor profile) showed no copper change, while clozapine (broad multireceptor antagonism) and aripiprazole (D2 partial agonism) both did. Asenapine's own EU SmPC (Section 5.1, directly fetched this pass): "Asenapine exhibits high affinity for serotonin 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5, 5-HT6, and 5-HT7 receptors, dopamine D2, D3, D4, and D1 receptors, alpha1 and alpha2-adrenergic receptors, and histamine H1 receptors," a breadth of binding that is structurally closer to clozapine's profile than to risperidone's, which is suggestive but not a demonstrated mechanism for asenapine specifically.

Counter-evidence held on record

This is disease-state and class-extrapolated evidence only, not evidence that asenapine itself changes copper status, and the within-class signal is split by receptor profile rather than uniform. Do not recommend copper supplementation, copper-lowering measures, or zinc supplementation for an asenapine-treated patient on this basis; if the mechanism applies to asenapine at all, the direction is a decrease, and copper's narrow safety margin argues against empiric supplementation without a measured low serum level.

Limits on what this shows

• Key negative/null findings: The same meta-analysis found a weaker, less consistent ferritin signal than the serum-iron signal, and the underlying studies were cross-sectional, so reverse causation (akathisia-related reduced appetite or food intake lowering iron) cannot be excluded. No study measuring iron status specifically in asenapine-treated patients was located in any channel reached this review.
• At-risk subgroups: Not established for asenapine specifically. By class-level analogy, patients on the highest labeled dose (10 mg twice daily), where asenapine's own akathisia incidence is highest (11 to 15 percent).
• Counter-evidence on record: Confounding by indication and by class-drug substitution is presumed until excluded (Hard Rule 6); no asenapine patient was in the iron/ferritin-measured cohort. Asenapine's own akathisia rate is a clinical outcome, not a nutrient measurement, cited here as context per Hard Rule 2, not as iron evidence. See Overlap map: this entry shares the Saghazadeh et al. 2020 source with Copper above.

Regulatory status

Neither the EU SmPC nor the US label mentions iron or ferritin. Akathisia is a labeled, dose-dependent adverse reaction, directly re-confirmed from the FDA label's adverse-reaction tables this pass: schizophrenia trials, 3% placebo versus 4% (5 mg twice daily) versus 11% (10 mg twice daily), 6% combined; bipolar mania trials, 2% placebo versus 4% (5 mg twice daily) versus 15% (10 mg twice daily), 6% combined. Extrapyramidal symptoms excluding akathisia follow a similar dose-dependent pattern (up to 12% schizophrenia, 11% bipolar mania at the 10 mg dose, versus 7% and 4% placebo respectively). No restless-legs-syndrome term appears in either label.

Population evidence

Schoretsanitis G, Nikolakopoulou A, Guinart D, Correll CU, Kane JM, Eur Neuropsychopharmacol 2020;35:1-11 (DOI 10.1016/j.euroneuro.2020.04.001, independently re-verified this pass via a direct Crossref DOI lookup, which returned the matching title, authors, journal, and volume/pages): systematic review/meta-analysis of 10 cross-sectional studies (n=395; 182 with akathisia, 213 without), serum iron significantly lower in patients with akathisia (SMD -0.49, 95% CI -0.70 to -0.28, p<0.001, fixed-effect model); ferritin showed a weaker signal. The included studies predate most newer antipsychotics and studied predominantly first-generation and early second-generation, full D2-antagonist agents, a pharmacological class asenapine itself belongs to (see Mechanism), unlike the D2-partial-agonist antipsychotics (aripiprazole, brexpiprazole, cariprazine) to which this same meta-analysis has been extrapolated elsewhere in this project. Asenapine was not in the iron-measured cohort. Separately, the Saghazadeh et al. 2020 disease-state meta-analysis cited under Copper above (39 studies, N=5151, PMID 31800085) reports, quoted, "lower levels of iron... among patients with schizophrenia vs controls," again disease-state rather than drug-specific.

Mechanism

The proposed mechanism in the non-asenapine literature is that low brain/serum iron impairs striatal D2 receptor function, lowering the threshold for extrapyramidal symptoms including akathisia. Asenapine's own EU SmPC-confirmed pharmacology is full antagonism, not partial agonism, at D1 through D4 dopamine receptors, mechanistically closer to the full D2-antagonist antipsychotics actually represented in the iron-akathisia literature than the partial agonists this same evidence has been extrapolated to elsewhere in this project; this makes the extrapolation somewhat better-fitted for asenapine than for those partial-agonist class members, though it remains unconfirmed for asenapine directly.

Counter-evidence held on record

Do not supplement iron in an asenapine-treated patient based on akathisia symptoms alone. Iron overload carries its own toxicity risk (NIH Office of Dietary Supplements tolerable upper intake level for elemental iron: 45 mg/day for adults from supplements); any repletion should follow a lab-confirmed low ferritin or iron panel and be prescriber-directed. This entry makes no standing dosing recommendation.

Limits on what this shows

• Key negative/null findings: PubMed search "asenapine AND (microbiome OR microbiota OR gut bacteria)" returned an explicit, clean zero-results page. A broader PubMed search for antipsychotics, gut microbiota, and (olanzapine OR risperidone OR asenapine) returned 49 results; the first page of results did not surface asenapine in any study cohort, and was dominated by olanzapine-specific work.
• At-risk subgroups: Not established for asenapine; if the class mechanism applies at all, patients with the largest weight-gain response would be the plausible subgroup, by analogy only.
• Counter-evidence on record: The Kamath et al. 2024 finding that lurasidone does not replicate olanzapine's dysbiosis is itself the most important counter-evidence here: it directly demonstrates that this is not a uniform class effect, which is the main reason this entry is graded yellow with a strong caveat rather than treated as a confident class-wide signal.

Regulatory status

Not addressed in the EU or US asenapine label.

Population evidence

Class member with real data, asenapine absent from cohort: Qian L, et al. "Longitudinal Gut Microbiota Dysbiosis Underlies Olanzapine-Induced Weight Gain." Microbiol Spectr. 2023; PMID 37260381 (olanzapine only). Kamath S, et al. "The atypical antipsychotics lurasidone and olanzapine exert contrasting effects on the gut microbiome and metabolic function of rats." Br J Pharmacol. 2024; PMID 39075330 (olanzapine and lurasidone only; found their effects diverge). Two further general/review-level sources were identified (Dias MF et al., "Effects of antipsychotics on the gastrointestinal microbiota: A systematic review," Psychiatry Res. 2024, PMID 38663221; Cheng W et al., "Schizophrenia and antipsychotic medications present distinct and shared gut microbial composition: A meta-analysis," Schizophr Res. 2024, PMID 39388810) but neither's full text or abstract could be opened during this review (both returned a bot-verification challenge page on every attempt), so whether either included asenapine in its underlying primary studies could not be confirmed; they are listed in Sources as inaccessible rather than used as supporting evidence.

Mechanism

Not established for asenapine specifically. The olanzapine dysbiosis literature proposes a route tied to olanzapine's own receptor pharmacology and metabolic/weight-gain liability; asenapine is a chemically distinct dibenzo-oxepino-pyrrole (not a thienobenzodiazepine like olanzapine) with a much smaller labeled weight-gain signal (mean 0.8 kg in combined trials versus several kilograms typically reported for olanzapine), so the strength of mechanistic transfer to asenapine is genuinely uncertain, not merely unconfirmed.

Counter-evidence held on record

This is class-extrapolated, not drug-specific, evidence (Tier C), and the one direct within-class comparison available argues against uniform extrapolation. No probiotic, prebiotic, or dietary supplementation claim is made or implied for asenapine on this basis.

Limits on what this shows

• Key negative/null findings: Despite sharing the implicated receptor mechanism, asenapine's own adverse-reaction tables, independently re-checked in full this pass, report no hemoglobin, hematocrit, white-blood-cell, total-protein, or albumin abnormality at any frequency, unlike iloperidone's label, which explicitly reports all five moving together. This is a meaningful null finding that bounds this entry to yellow rather than orange: the mechanism is shared, but the laboratory signal itself has not been demonstrated for asenapine. A separate ex vivo study (Pirc Marolt T et al., Antioxidants 2023, PMID 38001783, cited via companion-dossier cross-corroboration, not independently re-fetched this pass owing to persistent rate limiting) found aripiprazole, not olanzapine, caused in vitro erythrocyte destruction in donor blood; asenapine's broad multireceptor profile is pharmacologically closer to olanzapine, the null comparator in that experiment, than to aripiprazole, so that specific mechanism was considered and is not used to support this entry.
• At-risk subgroups: Not established for asenapine. By class analogy to iloperidone, higher-dose regimens and patients already close to anemia or hypoalbuminemia thresholds would be the plausible highest-risk group if the mechanism transfers at all.
• Counter-evidence on record: This is Tier C by definition: asenapine was absent from the only study showing this effect directly, and asenapine's own labeled lab data do not replicate it despite the shared receptor mechanism being present. Per Hard Rule 6, confounding and class-drug substitution are presumed until excluded, and are not excluded here.

Regulatory status

Neither the EU SmPC nor the US label lists anemia, hemoglobin, or hematocrit among asenapine's adverse reactions or lab-abnormality tables at any frequency, directly re-confirmed by fetching both the SAPHRIS and SECUADO DailyMed labels this pass. The only labeled hematologic term is neutropenia (rare), a white-cell, not oxygen-delivery, finding. Orthostatic hypotension is labeled (4.1% in elderly subjects versus 0.3% in the combined trial population, EU SmPC), but is excluded from grading here as the drug's own intended/incidental hemodynamic effect under Hard Rule 2, not treated as a nutrient-style finding in itself.

Population evidence

FANAPT (iloperidone) FDA label, Section 6.1, directly fetched and confirmed this pass: "there were 1.0% (13/1342) FANAPT-treated patients with hematocrit at least one time below the extended normal range during post-randomization treatment, compared to 0.3% (2/585) on placebo" in schizophrenia trials (10 to 24 mg/day), and "3.5% (7/200)... compared to 0.5% (1/196) on placebo" in bipolar-mania trials (up to 24 mg/day); the label states, "Analysis of clinical laboratory data following administration of FANAPT suggested the mechanism of hemodilution based on consistent decreases in hematocrit, hemoglobin, white blood cells, total protein, and albumin." Iloperidone was not in asenapine's own trial data; this is Tier A for iloperidone, Tier C class extrapolation for asenapine.

Mechanism

Plausibly related to plasma-volume expansion via high-affinity alpha1-adrenergic antagonism, the mechanism iloperidone's label names for its orthostatic-hypotension effect. Asenapine's EU SmPC (Section 5.1, directly confirmed this pass) documents the same qualitative "high affinity" binding at alpha1- and alpha2-adrenergic receptors and carries its own labeled orthostatic-hypotension signal, so the implicated mechanism is present for asenapine, though neither label quantifies asenapine's exact receptor-affinity potency relative to iloperidone's.

Counter-evidence held on record

This is a mechanism-shared but lab-signal-absent extrapolation, not confirmed evidence that asenapine itself changes hematocrit or hemoglobin. Do not use this entry to justify iron or hematinic supplementation in an asenapine-treated patient; if anemia or an unexplained hematocrit change is observed, it should be worked up on its own clinical merits rather than attributed to asenapine on the basis of this entry.

Limits on what this shows

• Key negative/null findings: Per companion-dossier citation, effect thresholds varied by drug rather than following one uniform potency, and a related finding in the same experimental program found no ATP reduction in primary forebrain neurons (only in ventral midbrain neurons) for cariprazine, arguing against a uniform, whole-brain effect even within the class members directly tested. No in vivo, human, or clinical energy-metabolism study (fatigue, exercise capacity, lactate, creatine phosphokinase) exists for any atypical antipsychotic in this family, let alone asenapine specifically.
• At-risk subgroups: Not established for asenapine; the findings come from toxicological, supratherapeutic in vitro exposure ranges only.
• Counter-evidence on record: No asenapine-specific mitochondrial-ATP data exist in either direction. The one asenapine-specific mitochondrial study located in this dossier (Grossini et al. 2014, graded under Mitochondrial burden and Oxidative stress above) measured membrane potential, reactive oxygen species, glutathione, and apoptosis, not ATP output directly, and runs in the protective rather than depleting direction; per this project's standing rule it is not extended to carry this entry independently.

Regulatory status

Not addressed in either label; no creatine-phosphokinase or energy-metabolism term appears in asenapine's adverse-reaction tables at any frequency.

Population evidence

Ľupták M, Fišar Z, Hroudová J, Mol Neurobiol 2021 (PMID 34365585, DOI 10.1007/s12035-021-02498-4): isolated pig brain mitochondria exposed to multiple antipsychotics; per matching citation in two independent companion dossiers in this project, "all tested antipsychotics decreased mitochondrial ATP production" at the higher of two tested concentrations (10 micromolar for brexpiprazole and lurasidone, 100 micromolar for cariprazine and loxapine), following dose-dependent inhibition of complex I- and/or complex II-linked respiration. The tested set spans both D2 partial agonists (cariprazine, brexpiprazole) and full D2 antagonists (lurasidone, loxapine); asenapine was not named among the drugs tested in either companion citation. A separate, narrower study (Hardy RE, Pryde KR et al., Biology Direct 2023, DOI 10.1186/s13062-023-00375-9, title confirmed via two independent companion-dossier citations: "The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors") found a specific ubiquinone-binding-site ("cork in a bottle") mechanism in exactly three D2-partial-agonist antipsychotics; asenapine, a full antagonist, was not tested, and this narrower mechanism is a weaker fit for asenapine's own pharmacology than the broader Ľupták et al. finding. This pass's own fresh fetch attempts for both DOIs (Crossref, PubMed, Europe PMC, OpenAlex) were blocked by HTTP 429 responses despite repeated tries across more than one host; both records are carried forward on cross-corroboration from matching PMID/DOI citation in multiple companion dossiers, disclosed here rather than presented as independently re-verified this pass.

Mechanism

Proposed as a direct downstream consequence of electron-transport-chain inhibition at concentrations roughly two to three orders of magnitude above typical therapeutic plasma levels for the class generally; not demonstrated for asenapine specifically, and the Q-site/"cork in a bottle" mechanism proposed for the partial-agonist subset does not obviously extend to a full antagonist like asenapine.

Counter-evidence held on record

Does not support ATP-support supplementation, such as coenzyme Q10, carnitine, or creatine, in patients on standard therapeutic asenapine dosing; no clinical trial evidence exists for this use in asenapine or in any class member at therapeutic concentrations.